Сardiac manifestations of post-­COVID syndrome: tachycardia

Abstract

Out of all the cardiac manifestations of post-COVID syndrome, tachycardia has been studied to a lesser extent, while almost all patients complain of palpitations.The purpose of the study is to reveal the incidence of post-COVID tachycardia syndrome in apparently healthy patients and to evaluate the effectiveness of ivabradine in this category of patients.Materials and methods. 48 patients revealing no comorbid pathology were examined 12 or more weeks after COVID-19. Materials of instrumental research methods, functional tests, quality of life before and during treatment with ivabradine were studied.Results. In all patients included in the study, against the background of an autonomic imbalance with a predominance of the activity of the sympathetic part and deterioration in quality of life, the syndrome of post-COVID tachycardia was diagnosed, and a positive effect of ivabradine on heart rate control was revealed.Conclusion. Tachycardia can be considered a marker of post-COVID syndrome in patients who were apparently healthy before coronavirus infection; it can manifest itself in POTS, NST, or their combination, as well as be accompanied by other cardiac arrhythmias including PVC, SVE, non-sustained SVT, and persistent form of AF. Ivabradine is able to control heart rate and level the manifestations of post-COVID tachycardia syndrome.